In addition, our own studies with transgenic mice that are prone to develop B cell lymphomas owing to a MYC transgene that is under the control of the immunoglobulin heavy chain or -lambda light chain enhancer and therefore constitutively expressed in follicular B cells or pre-germinal center B cells, respectively, confirmed this finding (Lacroix et al., 2022a). The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.